DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
D•• G••••••• S••
Pharmaceuticals, Biotechnology & Life Sciencesgroup grade Aoff every schedule since Mar 31, 2025sponsor unattributed
Also written as: 1; 2; Biotechnology & Life Sciences; Doc G•••••••; Pharmaceuticals
Nothing material in the last 200 days. Last change: 31 Mar 2025, Consensus mark 110¢ on cost, up from 104¢ in Q1 2024, 106¢ last quarter.
Mark path, consensus per quarter end
104¢ · 104¢ · 106¢ · 110¢Q1 2024 to Q1 2025
Principal held
at least $11.6M
sum of BDC pieces, a lower bound
Fair value
$12.5M
110c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
0 equity pieces beside them
Next maturity
Oct 1, 2028
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Mar 31, 2025
Events
2
dated, non-routine
Lender marks
each lender's own fair value over cost at Mar 31, 2025, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| F• K•• C•••••• C••• | $11.6M | 110¢ | +4 pts |
Every BDC piece · 1 position across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| F• K•• C•••••• C••• | unstated lien unstated | $11.6M | $12.5M 110c | S+550 bp |
Capital structure as the BDCs see it
latest quarter end Mar 31, 2025
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| other lien unstated exited Mar 31, 2025 | at least $11.6M | 110c | S+550 bp | Oct 1, 2028 | 1 |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2025 | 1 | $11.6M | $12.5M | 110c | 0 |
| Dec 31, 2024 | 1 | $28.0M | $29.0M | 106c | 0 |
| Sep 30, 2024 | 1 | $14.0M | $15.3M | 113c | 0 |
| Jun 30, 2024 | 1 | $14.0M | $15.1M | 111c | 0 |
All 10 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2024 | 1 | $14.0M | $14.9M | 110c | 0 |
| Dec 31, 2023 | 1 | $51.0M | $55.4M | 111c | 0 |
| Sep 30, 2023 | 1 | $25.5M | $26.5M | 106c | 0 |
| Jun 30, 2023 | 1 | $25.5M | $27.4M | 110c | 0 |
| Mar 31, 2023 | 1 | $25.5M | $26.9M | 108c | 0 |
| Dec 31, 2022 | 1 | $51.0M | $52.6M | 106c | 0 |
What changed
- Facility left every BDC scheduleMar 31, 2025
- Marked down (one lender)Dec 31, 2024
- New borrower on a BDC scheduleDec 31, 2022
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- DOC GENERICIderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Pharmaceuticals, Biotechnology & Life Sciencesreportedas one filer wrote it